Sugi Predict

Sugi Predict / Compounds / SCHEMBL10163489

SCHEMBL10163489

SCHEMBL10163489

CC(=O)c1ccccc1CNC(=O)c1cc(C(=O)NCc2ccc3oc(=O)n(C)c3c2)nc2c(F)cnn12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP13 P45452 2/20 0.41
▸ ADAMTS4 O75173 1/20 0.41
▸ MMP3 P08254 1/20 0.41
▸ MAPT P10636 5/20 0.40
▸ SMN1; SMN2 Q16637 4/20 0.40
▸ TP53 P04637 3/20 0.40
▸ ALDH1A1 P00352 8/20 0.36
▸ KDM4E B2RXH2 5/20 0.35
▸ LMNA P02545 5/20 0.35
▸ HPGD P15428 5/20 0.35
▸ HTT P42858 1/20 0.35
▸ THRB P10828 2/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ L3MBTL1 Q9Y468 2/20 0.34
▸ KMT2A Q03164 2/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ PPARG P37231 1/20 0.34
▸ NCOA2 Q15596 1/20 0.34
▸ NCOA1 Q15788 1/20 0.34
▸ NCOA3 Q9Y6Q9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8221163 0.93 MMP13 (0.40) MMP13ADAMTS4MMP3MAPTSMN1; SMN2
SCHEMBL10163511 0.93 TP53 (0.46) MMP13ADAMTS4MMP3MAPTSMN1; SMN2
SCHEMBL10163506 0.91 MMP13 (0.45) MMP13ADAMTS4MMP3MAPTTP53
SCHEMBL10163502 0.91 MMP13 (0.44) MMP13ADAMTS4MMP3MAPTTP53
SCHEMBL10163488 0.90 MMP13 (0.44) MMP13ADAMTS4MMP3MAPTSMN1; SMN2
SCHEMBL10163495 0.89 MMP13 (0.41) MMP13ADAMTS4MMP3MAPTTP53
SCHEMBL10163509 0.88 MMP13 (0.41) MMP13ADAMTS4MMP3MAPTSMN1; SMN2
SCHEMBL8225565 0.88 TP53 (0.43) MMP13ADAMTS4MMP3MAPTSMN1; SMN2
SCHEMBL8226231 0.88 MMP13 (0.40) MMP13ADAMTS4MMP3MAPTSMN1; SMN2
SCHEMBL8228853 0.87 ADAMTS4 (0.40) MMP13ADAMTS4MMP3MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 — — US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 — — US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 — — US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 — — US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 — — US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.